Thomasville National Bank Lowers Stock Position in Gilead Sciences, Inc. $GILD

Thomasville National Bank reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.5% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 105,495 shares of the biopharmaceutical company’s stock after selling 1,644 shares during the period. Thomasville National Bank’s holdings in Gilead Sciences were worth $11,696,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the stock. Vanguard Group Inc. lifted its position in shares of Gilead Sciences by 1.7% during the 1st quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company’s stock valued at $13,162,606,000 after buying an additional 1,942,433 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Gilead Sciences by 314.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock valued at $1,647,484,000 after buying an additional 11,156,382 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Gilead Sciences by 12.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 13,755,481 shares of the biopharmaceutical company’s stock valued at $1,541,302,000 after buying an additional 1,520,809 shares in the last quarter. Nuveen LLC purchased a new position in Gilead Sciences in the 1st quarter worth approximately $620,415,000. Finally, National Pension Service lifted its holdings in Gilead Sciences by 6.9% in the 1st quarter. National Pension Service now owns 3,473,373 shares of the biopharmaceutical company’s stock worth $389,191,000 after purchasing an additional 223,171 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts recently commented on GILD shares. Royal Bank Of Canada boosted their price target on Gilead Sciences from $96.00 to $98.00 and gave the stock a “sector perform” rating in a report on Friday, August 8th. Needham & Company LLC raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 price target on the stock in a report on Friday, July 25th. UBS Group boosted their price target on Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a report on Friday, August 8th. Dbs Bank raised Gilead Sciences to a “moderate buy” rating in a report on Friday, September 5th. Finally, JPMorgan Chase & Co. boosted their price target on Gilead Sciences from $135.00 to $145.00 and gave the stock an “overweight” rating in a report on Tuesday. Three analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $117.17.

Gilead Sciences Stock Up 0.4%

Shares of GILD opened at $114.09 on Friday. The stock has a market capitalization of $141.56 billion, a price-to-earnings ratio of 22.73, a price-to-earnings-growth ratio of 0.77 and a beta of 0.36. Gilead Sciences, Inc. has a 1 year low of $81.83 and a 1 year high of $121.83. The business’s 50 day simple moving average is $114.10 and its 200-day simple moving average is $110.06. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.96 by $0.05. The business had revenue of $7.08 billion for the quarter, compared to analysts’ expectations of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company’s revenue for the quarter was up 1.4% on a year-over-year basis. During the same period in the prior year, the firm earned $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, equities analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, September 29th. Stockholders of record on Monday, September 15th will be issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend is Monday, September 15th. Gilead Sciences’s dividend payout ratio is 62.95%.

Insider Transactions at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, August 28th. The stock was sold at an average price of $113.63, for a total transaction of $1,136,300.00. Following the transaction, the chief executive officer owned 595,725 shares of the company’s stock, valued at approximately $67,692,231.75. The trade was a 1.65% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $113.57, for a total value of $283,925.00. Following the transaction, the chief financial officer directly owned 159,555 shares in the company, valued at approximately $18,120,661.35. This represents a 1.54% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 82,000 shares of company stock valued at $9,390,030 in the last ninety days. Corporate insiders own 0.27% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.